Keywords: Human Genome Sciences, ABthrax, FDA, Anthrax, Research

US FDA panel seeks more ABthrax data from HGSI

Article | 2 November 2009

A panel of experts of the US Food and Drug Administration has recently asked for additional data to judge the efficacy of Human Genome Sciences Inc’s (HGSI) anthrax infection treatment ABthrax (raxibacumab) compared to existing anti-bacterial drugs. The panel of experts voted 17 to six, with one abstention, that the company should submit more evidence on whether adding ABthrax to older drugs is beneficial for anthrax treatment.

Data from studies had revealed that antibiotics used alone were highly effective against anthrax, thereby raising questions about the added benefit of ABthrax. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in